Dermata Therapeutics Inc
NASDAQ:DRMA

Watchlist Manager
Dermata Therapeutics Inc Logo
Dermata Therapeutics Inc
NASDAQ:DRMA
Watchlist
Price: 2.37 USD 16.18% Market Closed
Market Cap: 2.4m USD

Relative Value

DRMA doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of DRMA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DRMA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-14.1
Industry
21.7
Forward
-0.3
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-15.5
Industry
16.7
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-15.5
Industry
23.1
vs History
94
vs Industry
16
Median 3Y
10.4
Median 5Y
15.9
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
0
vs Industry
52
Median 3Y
-3.9
Median 5Y
-12.9
Industry
13.2
vs History
0
vs Industry
49
Median 3Y
-3.9
Median 5Y
-12.9
Industry
16.8
Forward
0.3
vs History
0
vs Industry
52
Median 3Y
-4.7
Median 5Y
-14.5
Industry
15.9
vs History
0
vs Industry
39
Median 3Y
-4.7
Median 5Y
-14.5
Industry
19.2
vs History
38
vs Industry
11
Median 3Y
-0.6
Median 5Y
0.6
Industry
1.9

Multiples Across Competitors

DRMA Competitors Multiples
Dermata Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Dermata Therapeutics Inc
NASDAQ:DRMA
2.4m USD 0 -0.3 0.2 0.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
500B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.5 158.8
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.3B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
Dermata Therapeutics Inc
NASDAQ:DRMA
Average P/E: 24.3
Negative Multiple: -0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Dermata Therapeutics Inc
NASDAQ:DRMA
Average EV/EBITDA: 399.1
0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
108.5
10%
10.8
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Dermata Therapeutics Inc
NASDAQ:DRMA
Average EV/EBIT: 1 710.5
0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
158.8
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3